LMO2 Antibody

中文名稱：

LMO2兔多克隆抗體
貨號：

CSB-PA013009HA01HU
規格：

￥440
圖片：
Western blot
All lanes: LMO2 antibody at 8 μg/ml + Mouse spleen tissue
Secondary
Goat polyclonal to rabbit IgG at 1/10000 dilution
Predicted band size: 19, 26, 6 kDa
Observed band size: 19 kDa

Immunohistochemistry of paraffin-embedded human tonsil tissue using CSB-PA013009HA01HU at dilution of 1:100
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) LMO2 Polyclonal antibody
Uniprot No.：

P25791
基因名：

LMO2
別名：

Cysteine rich protein TTG 2 antibody; Cysteine rich protein TTG2 antibody; Cysteine-rich protein TTG-2 antibody; LIM domain only 2 (rhombotin like 1) antibody; LIM domain only 2 antibody; LIM domain only protein 2 antibody; LMO 2 antibody; LMO-2 antibody; lmo2 antibody; RBTN 2 antibody; RBTN L1 antibody; RBTN2 antibody; RBTN2_HUMAN antibody; RBTNL 1 antibody; RBTNL1 antibody; RHOM 2 antibody; RHOM2 antibody; Rhombotin 2 antibody; Rhombotin like 1 antibody; Rhombotin-2 antibody; Rhombotin2 antibody; T cell translocation gene 2 antibody; T cell translocation protein 2 antibody; T-cell translocation protein 2 antibody; TTG 2 antibody; TTG2 antibody
宿主：

Rabbit
反應種屬：

Human, Mouse
免疫原：

Recombinant Human Rhombotin-2 protein (1-100AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，LMO2 Antibody (CSB-PA013009HA01HU)，的標記方式是Non-conjugated。對于LMO2 Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA013009HB01HU	LMO2 Antibody, HRP conjugated	ELISA
FITC	CSB-PA013009HC01HU	LMO2 Antibody, FITC conjugated
Biotin	CSB-PA013009HD01HU	LMO2 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, WB, IHC

推薦稀釋比：

Application	Recommended Dilution
WB	1:1000-1:5000
IHC	1:20-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Acts with TAL1/SCL to regulate red blood cell development. Also acts with LDB1 to maintain erythroid precursors in an immature state.
基因功能參考文獻：
1. the data in this study revealed a novel crosstalk between LMO2 and the Wnt signaling pathway during tumorigenesis and suggested that LMO2 might be a tumor suppressor in certain solid tumors. PMID: 27779255
2. LMO2 has a predominantly cytoplasmic location in breast cancer cells. LMO2 interaction with cofilin1 regulates actin cytoskeleton dynamics, promoting tumor cell invasion and metastasis. PMID: 27880729
3. These data indicate that Lhx2 is capable of blocking proliferation of T-ALL-derived cells by both LMO2-dependent and -independent means. We propose Lhx2 as a new molecular tool for anti-T-ALL drug development. PMID: 29278703
4. stromal LMO2 may be responsible for zonal characteristic of Prostate cancer PMID: 27028859
5. The transcriptional factor LMO2 regulates endothelial proliferation and angiogenesis in vitro. PMID: 27792641
6. This article demonstrates a novel and unexpected function of the LMO2 oncogenic transcription factor in controlling DNA replication that we unravelled via an unbiased proteome-wide screen for LMO2-interacting partners. PMID: 26764384
7. Findings suggest that LMO2 loss may be a good predictor for the presence of MYC translocation in large B-cell lymphoma. PMID: 28288039
8. FOXP3 binds LMO2 in vitro, resulting in decreased interaction between LMO2 and TAL1, providing a molecular mechanism for FOXP3-mediated transcriptional modulation in T-ALL. PMID: 26686090
9. recurrent activating intronic mutations of LMO2, a prominent oncogene in T-cell acute lymphoblastic leukemia (T-ALL). Heterozygous mutations were identified in PF-382 and DU.528 T-ALL cell lines in addition to 3.7% of pediatric (6 of 160) and 5.5% of adult (9 of 163) T-ALL patient samples. PMID: 28270453
10. Data indicate a novel functional mechanism of LMO2 in facilitating the delivery of actin monomers to the branched microfilament and increasing lamellipodia/filopodia formation in basal-type breast cancer cells. PMID: 28170369
11. we demonstrate previously unrecognized mechanisms by which LMO2 alters human T-cell development in vivo; these mechanisms correlate with human T-ALL leukemogenesis. PMID: 27302866
12. this study revealed a novel function of LMO2 involving in the regulatory hierarchy of UBA6-USE1-FAT10ylation pathway by targeting the E1 enzyme UBA6. PMID: 27569286
13. LMO2 is a useful marker for immunophenotypic assessment of thymic neoplasms. PMID: 26796495
14. LMO2 was associated with increased levels of cytosolic p27(Kip1) protein. PMID: 26383528
15. that suppression of MIR223 expression, as compared with controls, is associated with lack of differentiation and adverse cytogenetic profile, but unrelated with LMO2 protein expression or overall survival. PMID: 25710580
16. Alanine scanning mutagenesis of the LIM interaction domain of LDB1 revealed a discrete motif, R(320)LITR, required for LMO2 binding. PMID: 26598604
17. LMO2 expression was elevated in GBM tissues and inversely correlated with prognosis of GBM patients. Taken together, our findings describe novel dual roles of LMO2 to induce tumorigenesis and angiogenesis. PMID: 25721045
18. Diagnostic Utility of the Germinal Center-associated Markers GCET1, HGAL, and LMO2 in Hematolymphoid Neoplasms. PMID: 25203428
19. Data show that the Lim domain only 2 (LMO2) regulatory element (element-25) region consists of transcription factor GATA2-binding myeloid ennhancer and RUNX protein-binding T-cell repressor. PMID: 26161748
20. Cryptic chromosomal rearrangements in the LMO2 gene were associated with T-cell acute lymphoblastic leukemia. PMID: 25682596
21. results suggest that E47 has diverse effects in T-ALL but that functional deficiency of E47 is not a universal feature of Lmo2-induced T-ALL. PMID: 25499232
22. HHEX is a direct transcriptional target of LMO2 consistent with its concordant gene expression. PMID: 24465765
23. LMO2 is expressed in a subset of acute myeloid leukaemia patients and is associated with normal karyotype, which is different from T lymphoblastic lymphoma/leukaemia, where specific translocation (11p13) mediates protein expression. PMID: 24330148
24. GATA2 and Lmo2 cooperatively regulate VEGF-induced angiogenesis and lymphangiogenesis via NRP2. PMID: 23892628
25. In t(8;21) leukemia cells, LMO2 functions as a component of the stable AML1-ETO-containing transcription factor complex (AETFC). The AETFC components cooperatively regulate gene expression and contribute to leukemogenesis. PMID: 23812588
26. a regulatory hierarchy of HOX control of LMO2 in normal development PMID: 23708655
27. Staining for LMO2 in addition to CD10 and BCL6 facilitates the detection of a germinal center phenotype in follicular lymphoma PMID: 23897248
28. HGAL and LMO2 may be useful adjuncts in the identification of follicular lymphoma of the nongastric gastrointestinal tract. PMID: 22914613
29. LMO2 expression is a special feature of germinal center diffuse large B cell lymphomas. PMID: 22776842
30. Transcriptional regulators cooperate to establish or maintain primitive stem cell-like signatures in leukemic cells. PMID: 23327922
31. The new anti-LMO2 antibody can be applied confidently to routine sections, contributing to the differential diagnosis of several lymphoma subtypes, subtyping of DLBCLs and potential development of innovative therapies. PMID: 22394247
32. Germline genetic variation in LMO2 was associated with diffuse large B-cell lymphoma prognosis and provided slightly stronger predictive ability relative to LMO2 immunohistochemistry status. PMID: 22066713
33. evidence that the H3K9-me1/2 demethylase KDM3B might play a role in leukemogenesis via activation of lmo2 through interdependent actions with the histone acetyltransferase complex containing CBP PMID: 22615488
34. Overexpression of LMO2 in diffuse large B-cell (DLBCL) cell lines results in centrosome amplification. PMID: 22517897
35. B-cell acute lymphoblastic leukemia cases expressed variable levels of LMO2 depending on immunophenotypical and cytogenetic features PMID: 21459790
36. SStudies suggest that the expression of LMO2 protein in lymphoma tissue biopsies predicts survival in patients with RA who have developed DLBCL PMID: 21375434
37. Data suggest that both HGAL and LMO2 are directly regulated by the transcription repressor PRDM1--overexpression of PRDM1 down-regulates HGAL and LMO2; PRDM1 directly binds to promoters of both HGAL and LMO2 and represses genetic transcription. PMID: 21722313
38. The measurement of a single gene expressed by tumor cells (LMO2) and a single gene expressed by the immune microenvironment (TNFRSF9) powerfully predicts overall survival in patients with diffuse large B-cell lymphoma. PMID: 21670469
39. LMO2 is sensitive and specific marker for detecting follicular lymphoma in nodal and extranodal sites PMID: 21502424
40. both Lmo2 and Bcl-2 are required for the action of E2A-HLF in leukemogenesis PMID: 21072044
41. first structural model of the DNA-binding complex containing LMO2, LDB1, SCL/TAL1, and GATA-1 PMID: 21076045
42. Multiple-wavelength anomalous dispersion (MAD) data have been collected at the zinc X-ray absorption edge to a resolution of 2.8 A and the data were used to solve the structure of the LMO2:Ldb1-LIM-interaction domain complex. PMID: 21045296
43. LMO2 probably promotes angiogenesis by up-regulation of bFGF expression and thereby consequently influences progression of infantile haemangiomas PMID: 20955387
44. As LMO2 controls hematopoiesis, its dysregulation is leukemogenic PMID: 21059912
45. Overexpression of either KLF1 or LMO2 partially rescued the defect in erythropoiesis caused by c-myb silencing, whereas only KLF1 was also able to repress the megakaryocyte differentiation enhanced in Myb-silenced CD34+ cells. PMID: 20686118
46. ectopically expressed LMO2 impaired the function of DeltaEF1 in both transcriptional and protein levels and identified DeltaEF1 as a novel pathogenic target of LMO2 in T-cell leukemia. PMID: 20731704
47. a self-sustaining triad of LMO2/ERG/FLI1 stabilizes the expression of important mediators of the leukaemic phenotype such as HHEX/PRH. PMID: 20676125
48. We report that LMO2 protein is expressed in a significant proportion of B-ALL and AML and the staining of LMO2 protein does not predict survival in acute leukemia. PMID: 20557670
49. E2A-HLF promotes cell survival of t(17;19)- acute lymphoblastic leukemia cells by aberrantly up-regulating LMO2 expression PMID: 20519628
50. Our results show that HGAL and LMO2 are sensitive markers for follicular lymphoma diagnosis. PMID: 20697248
顯示更多

收起更多
相關疾病：

A chromosomal aberration involving LMO2 may be a cause of a form of T-cell acute lymphoblastic leukemia (T-ALL). Translocation t(11,14)(p13;q11) with TCRD.
亞細胞定位：

Nucleus.
數據庫鏈接：

HGNC: 6642

OMIM: 180385

KEGG: hsa:4005

STRING: 9606.ENSP00000257818

UniGene: Hs.34560

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VDR Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
VDAC1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human, Mouse, Rat